Search results for: Antibiotics
Filter search results
The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance
12 October 2022
…As a result, prices for antibiotics, and therefore the rewards for innovation, do not reflect the true value of antibiotics, further weakening incentives [2]. If antibiotics do reach the market…
The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?
12 October 2022
…of novel antibiotics globally. Companies also have a role to play in ensuring access to novel antibiotics in LMIC countries. With combined action valuable new antibiotics could then be shared…
The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot
12 October 2022
…antibiotics explained why markets fail to incentivise the development of novel antibiotics. It also outlined how England has spearheaded efforts to test a potential solution to this challenge through a…
The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics
12 October 2022
…AMR Pilot Part 3: Creating a Healthy Global Market for New Antibiotics Part 4: What Does the Antibiotics Market of the Future Look like? References BCG, 2022. Incentivizing Innovation to…
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
…Antibiotics. Policy Brief. Center for Global Development. Available at https://www.cgdev.org/publication/estimating-canadas-return-investment-ambitious-program-incentivize-new-antibiotics Silverman Bonnifield R and Towse A. 2022 Estimating Japan’s Return on Investment from an Ambitious Program to Incentivize New Antibiotics….
How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.
26 March 2020
…contracting for new antibiotics. It analyses UK (NICE and NHSE) plans to introduce a subscription model (delinking use of new antibiotics from payments for making the products available) and suggests…
New Business Models for Antibiotics. What Can We Learn from Other Industries?
7 April 2015
…As resistance to antibiotics continues to grow, there is a well-recognised misalignment between the clinical need for new antibiotics and the incentives for their development. Partly as a result, there…
Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
16 January 2024
…National Institute for Health and Care Excellence (NICE) and NHS England trialled a volume-delinked subscription-type model for two antibiotics for severe infections resistant to the last line of antibiotics (NICE,…
Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions
30 May 2017
…is unique to antibiotics and is not explicitly considered by HTA bodies. Non-clinical and microbiology data are important for demonstrating the value of antibiotics. For antibiotics, non-clinical and microbiology data…